Fisher & Paykel HealthcareASX:FPH +0.06%90 5-Year Yield-on-Cost % is 1.66 as of Jul. 09, 2026, which is 3% below its 10-year median of 1.71. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.36 (Fairly Valued). The stock has 2 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 59.33% on this metric.
The historical rank and industry rank for Fisher & Paykel Healthcare's 5-Year Yield-on-Cost % or its related term are showing as below:
ASX:FPH'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.87 Med: 1.71 Max: 2.74
Current: 1.66
During the past 13 years, Fisher & Paykel Healthcare's highest Yield on Cost was 2.74. The lowest was 0.87. And the median was 1.71.
ASX:FPH's 5-Year Yield-on-Cost % is ranked worse than 59.33% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.39
vs ASX:FPH: 1.66
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Fisher & Paykel Healthcare 5-Year Yield-on-Cost % Related Terms
ASX:FPH vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Fisher & Paykel Healthcare (ASX:FPH) has a 5-Year Yield-on-Cost % of 1.66 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 1.71. Over the past decade, Fisher & Paykel Healthcare's 5-Year Yield-on-Cost % has ranged from 0.87 to 2.74. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #194 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 59.3%.
Is Fisher & Paykel Healthcare's 5-Year Yield-on-Cost % too high?
Fisher & Paykel Healthcare's current 5-Year Yield-on-Cost % of 1.66 is near median its 10-year median of 1.71. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 2.74. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.39. Fisher & Paykel Healthcare's value of 1.66 is 30.5% below this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #194 out of 327 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #194 out of 327 companies for 5-Year Yield-on-Cost %. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. Fisher & Paykel Healthcare's value of 1.66 is 30.5% below this benchmark. Historically, Fisher & Paykel Healthcare's own 5-Year Yield-on-Cost % has ranged from 0.87 to 2.74 over the past decade. While the company's 10-year median is 1.71 vs. the industry median of 2.39, Fisher & Paykel Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.39, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current 5-Year Yield-on-Cost % of 1.66 is 30.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current 5-Year Yield-on-Cost % is 1.66, which is near median its own 10-year median of 1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.36, compared to a current price of A$33.01 — trading 9.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.66, which is near median its 10-year median of 1.71 and 30.5% below the Medical Devices & Instruments industry median of 2.39. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current 5-Year Yield-on-Cost % is 1.66 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$33.01 is trading 9.2% below its estimated GF Value™ of A$36.36.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
5-Year Yield-on-Cost %: 1.66 (near median its 10-year median of 1.71)
GF Value™: A$36.36 vs. price of A$33.01 (9.2% below fair value)
Industry Position: 30.5% below the Medical Devices & Instruments median (#194 of 327)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for ASX:FPH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 